sansrosa articles ↓

A recent investor presentation from Collagenex gives some hints as to how Collagenex will price COL-118. Collagenex believe that their anti erythema product used for  2-4 months of treatment at $150 a month leads to a $330-660 million market. $150 a month for COL-118 treatment sounds like a lot. One wonders how much the suggested $150 a month will translate to at the …

PubMed pushed out an interesting abstract in the last couple of days. A bit of digging reveals what looks to be a running mate for COL-118/Sansrosa. COL-118 and Oxymetazoline appear to be promoted by separate groups of researchers.

This is good news for rosacea sufferers as it means there may well be a choice between 2 topicals that can help address the redness and flushing …

As was mentioned in January this year, COL-118 (product code used for the sansrosa product) is expected to move from Phase 1 to Phase 2 in 2007. Collagenex has published results from their Phase 2 trials that were conducted in order to test some dosage levels to assess how they effective they are and also any side effects. Some interesting points in their press release: CollaGenex …

Collagenex has confirmed that sansrosa (now called COL-118) is due to move from Phase 1 to Phase 2 some time in 2007. This confirms that COL-118 is still several years away from becoming generally available:

From: Collagenex Pharmaceuticals CEO Speaks About His Company, Jan 8, 2007.
In addition to that, we also have a compound, which is undisclosed at the moment, but referred to as COL-118, …

Andrew has added some more to his excellent ongoing commentary about Sansrosa.

A recent blog post titled Alphagan P (0.15% brimonidine) and SansRosa, makes the suggestion that the interesting looking Sansrosa invention may have started life as eye drops for glaucoma.

Reading the side effects of `Alphagan P’ is pretty sobering, so if indeed the suggested link from the drops to Sansrosa is correct, the real …